CHENGDU, China, June 20, 2025 /PRNewswire/ -- On June 20, the "Global Connectivity • Industrial Interaction" International Sports Industry Salon was held in Hong Kong. The event was hosted by National Business Daily, organized by NBD Think Tank Hong Kong Center, and supported by Chengdu Sports Federation, Hong Kong Commercial Daily, and COJOY, which attracted over 50 representatives, including business leaders, experts and industry pioneers from the sports sectors of Hong Kong and Chengdu. They gathered to engage in in-depth discussions on topics such as how the sports industry can promote urban development and enhance cross-regional cooperation.
Darren Burden, Chief Operating Officer of Kai Tak Sports Park in Hong Kong, introduced the design philosophy and operational model of the Kai Tak Sports Park – Hong Kong's largest-ever sports infrastructure project. He stated, "The Kai Tak Sports Park is not only the main venue for the Hong Kong events of the 15th National Games of the People's Republic of China but is fast becoming a new landmark for sports and entertainment in Hong Kong." While Ismael Martinez Merchan, Senior Associate and Project Architect of the prestigious sports architecture design firm Populous, shared the company's leading experience in global sports venue design and specifically showcased how the design of the Kai Tak Sports Park integrates local cultural elements with an international perspective.
Chengdu is set to host The World Games 2025 Chengdu in August. Hence, the event featured a special "Promotion for Chengdu World Games," inviting Geely Holding Group, an official partner of the Games, to share insights on "How Major Sports Events Empower City Branding." The Group's Head of Brand Strategy remarked, "The World Games are not only a stage for competition but also a window to showcase a city's culture and innovation capabilities." Additionally, representatives from famous AG E-sports Club (Chengdu) and Chengdu Happy Sports Development Group introduced their respective business developments and achievements over the years.
During the panel discussion, experts discussed on topics like "how to further enhance city visibility and influence through international sports events" and unanimously agreed that the sports industry has become a new engine driving urban economic, cultural, and social development.
The successful hosting of the Sports Salon marked the completion of the International Salon Series. The organizer expressed its commitment to more similar high-level dialogues in the future, promoting exchanges between Chengdu's various industries and the global community.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
"Global Connectivity • Industry Interaction" International Sports Industry Salon Held in Hong Kong
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
